13th May 2015 15:00
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | AstraZeneca PLC | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to thenotification obligation: iii | The Capital Group Companies, Inc. | |||
4. Full name of shareholder(s) (if different from 3.):iv | See Schedule A | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 11 May 2015 | |||
6. Date on which issuer notified: | 12 May 2015 | |||
7. Threshold(s) that is/are crossed orreached: vi, vii | Above 3% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
Ordinary Shares (ISIN: GB0009895292) | 32,100,333 | 32,100,333 | 32,139,533 | 2.544% | ||||||||||||
ADRs (ISIN: US0463531089) | 5,767,760 | 5,767,760 | 5,768,891 | 0.457% | ||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
37,908,424 | 3.000% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
See Schedule A | ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | ||
14. Contact name: | Martin Bennett, Assistant Company Secretary | |
15. Contact telephone number: | 020 7604 8157 | |
Schedule A
As of 11 May 2015
AstraZeneca PLC
Number of Shares | Percent of Outstanding | |
The Capital Group Companies, Inc. ("CG") holdings | 37,908,424 | 3.000% |
Holdings by CG Management Companies and Funds: | ||
Capital Guardian Trust Company | 5,439,762 | 0.431% |
Capital International Limited | 165,000 | 0.013% |
Capital International Sàrl | 153,792 | 0.012% |
Capital International, Inc. | 72,300 | 0.006% |
Capital Research and Management Company | 32,077,570 | 2.539% |
Related Shares:
Astrazeneca